Rubius Therapeutics to Announce First Quarter 2021 Financial Results
Rubius Therapeutics (Nasdaq: RUBY) announced plans to report its first-quarter financial results on May 10, 2021, before market open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rubius Therapeutics (Nasdaq: RUBY) announced plans to report its first-quarter financial results on May 10, 2021, before market open. The company specializes in Red Cell Therapeutics™ aimed at treating cancer and autoimmune diseases. Their proprietary RED PLATFORM® allows for the genetic engineering of red blood cells, enhancing their therapy's potential. Notably, the company will not hold a teleconference to discuss these results following the release.
Positive
- Focus on novel Red Cell Therapeutics™ for cancer and autoimmune treatments.
- Recognition as one of the Top Places to Work in Massachusetts.
Negative
- None.
Details
News Market Reaction – RUBY
The recorded move for RUBY in the trading session of this news was -0.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report first quarter financial results on Monday, May 10, 2021, before market open.
The company will not be hosting a teleconference in conjunction with its financial results press release.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates, for the treatment of cancer and autoimmune diseases, by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.
Contacts:
Elhan Webb, CFA
Vice President, Investor Relations
elhan.webb@rubiustx.com
Media:
Marissa Hanify
Director, Corporate Communications
marissa.hanify@rubiustx.com
Dan Budwick
1AB
+1 (973) 271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.